Table 2.
Characteristics of the studies included to assess the demographic characteristics, co-morbidities and clinical warning signs of severe dengue
| Parameters | Frequency (n) | Percentage (%) |
|---|---|---|
| WHO Classification type | ||
| 1997 | 58 | 40.6 |
| 2009 | 85 | 59.4 |
| WHO region | ||
| South-East Asia | 74 | 51.8 |
| Western Pacific | 33 | 23.1 |
| American | 26 | 18.2 |
| Eastern Mediterranean | 7 | 4.9 |
| European | 2 | 1.4 |
| Africa | 1 | 0.7 |
| Study design | ||
| Case control | 26 | 18.2 |
| Cohort | 36 | 25.2 |
| Cross-sectional | 81 | 56.6 |
| Study population | ||
| Children | 59 | 41.3 |
| Adults | 36 | 25.2 |
| Mixed | 47 | 32.9 |
| No information | 1 | 0.7 |
| Recruitment year | ||
| 1990–2010 | 78 | 54.6 |
| 2011–2019 | 64 | 44.8 |
| No information | 1 | 0.7 |
| Laboratory diagnosis | ||
| ELISA | 96 | 67.1 |
| PCR | 49 | 34.3 |
| RDT | 27 | 18.9 |
| HI | 10 | 7.0 |
| Viral culture | 4 | 2.8 |
| Immunohistochemistry | 2 | 1.4 |
| Immunofluorescence assay | 1 | 0.7 |
| Neutralization test | 1 | 0.7 |
| Dotblot immuno assay | 1 | 0.7 |
| No information | 13 | 9.1 |
ELISA enzyme linked immunosorbent assay, PCR polymerase chain reaction, RDT rapid diagnostic test, HI haemagglutination inhibition